


CENTER FOR  
CANCER  
RESEARCH

Connecting the Cancer Community




• Innovative Science

• Breakthrough Therapies


• Clinical Advances

## An ES Cell-Based Functional Assay to Study BRCA2 Variants




TECH  
Council MD

**TEDCO/NIH/NCI Technology Showcase**




TEDCO  
Technology Development Corporation

**Shyam K. Sharan**  
September 25, 2007



NATIONAL INSTITUTES  
OF HEALTH  
NATIONAL INSTITUTE  
OF CANCER

## *Hereditary Breast Cancer: BRCA1 & BRCA2*



CENTER FOR CANCER RESEARCH

- Lifetime risk of breast cancer in general population is ~13.2% but *BRCA1* and *BRCA2* carriers have 36-85%
- *BRCA1* consists of 1863 amino acids and *BRCA2* protein has 3418 amino acids
- Mutations are scattered throughout the gene: no hot spots

## *BRCA1 and BRCA2 Mutation Spectrum\**



Mutation Type	Frequency	
	<i>BRCA1</i>	<i>BRCA2</i>
Frame-shift	5805	3436
Single aa change	3559	6168
Nonsense	1309	996
Intronic	1075	438
5' UTR	5	88
In-frame deletion	64	46
In-frame insertion	3	16


\*Source: Breast Cancer Information Core

## *Cancer Predisposing Mutation or Polymorphism?*




- Functional significance of mutations other than frame-shift alterations is unknown
- Lack of suitable functional assay
- Segregation of the disease with the mutation
- Prevalence of the mutation in general population



## Analyzing functional significance of BRCA2 mutations in ES cells



## Human BRCA2 Can Rescue ES cell Lethality




## Y3308X Mutant cells are Viable but Hypersensitive to Genotoxins



## Y3308X cells Exhibit Genomic Instability




*Brca2 +/-*




Y3308X

## Is E3309X Deleterious or a Polymorphic Variation?



## Scheme to Examine Human Missense Mutations in ES cells



## *Application in Genetic Counseling*



- 10,000 individuals with personal or family history of cancer were screened for *BRCA1* and *BRCA2* mutations by Myriad Genetics\*.
- 5503 indicated a personal history of breast or ovarian cancer
- 17% had deleterious mutations, 13% had one or more variants of unknown clinical significance
- The assay can be used to determine the functional significance of unknown variants

*\* Journal of Clinical Oncology (2002) 20, 1480-1490.*

## *Contact Information*



- ***For further information contact:***

Shyam K. Sharan  
Mouse Cancer Genetics Program  
CCR, NCI-Frederick  
Frederick, MD

Phone: (301) 846-5140  
email: [ssharan@ncifcrf.gov](mailto:ssharan@ncifcrf.gov)